Clinical Immunotherapeutics

, Volume 1, Issue 4, pp 245–249 | Cite as

Monoclonal Antibodies in Rabies Therapy

  • Bernhard Dietzschold
Leading Article


Virus-neutralising antibodies play a major role in immunological protection against rabies. A combination of anti-rabies immunoglobulin and vaccine has become the standard World Health Organization treatment for humans with severe exposure to rabies virus. Equine anti-rabies serum (ERIG) and human rabies immunoglobulin (HRIG) are currently used for rabies post-exposure serotherapy. These products are either extremely expensive or their use is associated with adverse effects, as in the case of ERIG. Therefore, it is desirable to replace ERIG and HRIG by more cost effective and safer products.

Recent studies have shown that passive immunisation of rodents with murine or human monoclonal antibodies (mAbs) specific for the G protein of rabies virus protects from the disease in a post-exposure situation. Such treatment can also abrogate a lethal rabies virus infection after the virus has entered the central nervous system. These findings indicate the great potential of antiviral mAbs as effective therapeutics against rabies. Because of their highly specific protective activity and the lack of major risks and adverse effects, these mAbs have a major advantage over hyperimmune globulins.

However, there still exist inherent problems in the clinical application of mAbs. The high immunogenicity of murine mAbs in humans and the risk of virus contamination of human mAb preparations represent major obstacles for the use of mAbs. Recombinant DNA technology can be used to humanise murine mAbs. This increases the biological half-life and minimises the possibility of adverse effects. The problem of possible virus contamination of mAb preparations can be overcome by the expression of the mAb in a heterologous system.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Steele HH. Rabies in the Americas and remarks on global aspects. Rev Infect Dis 1988; 10 (Suppl. 4): 585–97CrossRefGoogle Scholar
  2. 2.
    Baer GM. Research towards rabies prevention: overview. Rev Infect Dis 1988; 10 (Suppl. 4): 576–8CrossRefGoogle Scholar
  3. 3.
    Dietzschold B, Tollis M, Lafon M, et al. Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies. Virology 1987; 161: 29–36PubMedCrossRefGoogle Scholar
  4. 4.
    Davis DR, Metzger H. Structural basis of antibody function. Annu Rev Immunol 1983; 1: 87–117CrossRefGoogle Scholar
  5. 5.
    Dietzschold B, Ertl HCJ. New developments in the pre- and post-exposure treatment of rabies. Crit Rev Immunol 1991; 10: 427–39PubMedGoogle Scholar
  6. 6.
    Dietzschold B, Kao M, Zheng YM, et al. Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci USA 1992; 89: 7252–6PubMedCrossRefGoogle Scholar
  7. 7.
    Dietzschold B. Antibody-mediated clearance of viruses from the mammalian central nervous system. Trends Microbiol 1993; 1: 63–5PubMedCrossRefGoogle Scholar
  8. 8.
    Wiktor TJ, Koprowski H. Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. Proc Natl Acad Sci USA 1978; 75: 3938–40PubMedCrossRefGoogle Scholar
  9. 9.
    Ueki Y, Goldfarb IS, Harindranath N, et al. Clonal analysis of a human antibody response: quantitation of precursors and antibody-producing cells and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med 1990; 171: 19–34PubMedCrossRefGoogle Scholar
  10. 10.
    Dietzschold B, Gore M, Casale P, et al. Biological characterization of human monoclonal antibodies to rabies virus. J Virol 1990; 64: 3087–90PubMedGoogle Scholar
  11. 11.
    Turner GS. Immunoglobulin (IgG and IgM) antibody responses to rabies vaccine. J Gen Virol 1978; 40: 595–604PubMedCrossRefGoogle Scholar
  12. 12.
    Schumacher CL, Dietzschold B, Ertl HCJ, et al. Use of mouse anti-rabies monoclonal antibodies in post-exposure treatment of rabies. J Clin Invest 1989; 84: 971–5PubMedCrossRefGoogle Scholar
  13. 13.
    Sears H, Herlyn D, Steplewski Z, et al. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Resp Mod 1984; 3: 138–50Google Scholar
  14. 14.
    Massuci G, Ragnhammer P, Frödin JE, et al. Chemotherapy and immunotherapy of colorectal cancer. Med Oncol Tumor Pharmacother 1991; 8: 207–20Google Scholar
  15. 15.
    Reichman L, Clark M, Waldman H, et al. Reshaping human antibodies for therapy. Nature 1988; 332: 323–7CrossRefGoogle Scholar
  16. 16.
    Co MS, Deschamps M, Whitley RJ, et al. Humanized antibodies for antiviral therapy. Proc Natl Acad Sci USA 1991; 88: 2869–73PubMedCrossRefGoogle Scholar
  17. 17.
    Hasemann CA, Capra JD. High-level production of a functional immunoglobulin heterodimer in a baculovirus expression system. Proc Natl Acad Sci USA 1990; 87: 3942–6PubMedCrossRefGoogle Scholar
  18. 18.
    Cheung SC, Dietzschold B, Koprowski H, et al. A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus. J Virol 1992; 66: 6714–20PubMedGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Bernhard Dietzschold
    • 1
  1. 1.Department of Microbiology and Immunology, Center for Neurovirology, Jefferson Alumni Hall #459Thomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations